Evidence map›Paper›PMID 39202271›Full record

ArticleDiagnostics (Basel, Switzerland)2024

Analytical Validation of a DNA Methylation Biomarker Test for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma from Samples Collected Using EsoCheck

Abhisek Ghosal, Suman Verma, Ivy T Le, Victoria T Lee, Brian J deGuzman, Lishan Aklog

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Abhisek GhosalLucid Diagnostics, 360 Madison Ave., Floor 25, New York, NY 10017, USA.
Suman VermaLucid Diagnostics, 360 Madison Ave., Floor 25, New York, NY 10017, USA.ORCID 0009-0005-2305-3986
Ivy T LeLucid Diagnostics, 360 Madison Ave., Floor 25, New York, NY 10017, USA.
Victoria T LeeLucid Diagnostics, 360 Madison Ave., Floor 25, New York, NY 10017, USA.
Brian J deGuzmanLucid Diagnostics, 360 Madison Ave., Floor 25, New York, NY 10017, USA.
Lishan AklogLucid Diagnostics, 360 Madison Ave., Floor 25, New York, NY 10017, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Barrett's esophagus (BE) is a known precursor to esophageal adenocarcinoma (EAC). Guidelines recommend BE screening in populations with multiple risk factors, for which non-endoscopic esophageal cell collection with biomarker testing is considered as an acceptable alternative to esophagogastroduodenoscopy (EGD). The aim of this study was to evaluate analytical performance characteristics of EsoGuard

Indexed as

analytical validationBarrett’s esophagus (BE)Clinical Laboratory Improvement Amendments (CLIA)College of American Pathologists (CAP)cyclin A1 (CCNA1)DNA methylation biomarkerearly detectionesophageal adenocarcinoma (EAC)laboratory-developed test (LDT)vimentin (VIM)

Identifiers

PMID39202271
PMCPMC11354049

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.